Analine Almojera de Leus
Family · Whittier, CANPI 1841615895
Payments from drug & device makers
Across 137 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$851
- Lilly USA, LLC$478
- Bayer$327
- Astellas Pharma US Inc$267
- Amgen$189
- Otsuka America Pharmaceutical, Inc.$126
- plus $480 from 8 others
What the payments were for
- Food & beverage$2,62997%
- Education$893%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $851 |
| Lilly USA, LLC | 24 | $478 |
| Bayer | 15 | $327 |
| Astellas Pharma US Inc | 8 | $267 |
| Amgen | 7 | $189 |
| Otsuka America Pharmaceutical, Inc. | 6 | $126 |
| Kowa Pharmaceuticals America, Inc. | 6 | $124 |
| Merck | 5 | $108 |
| Boehringer Ingelheim | 4 | $70 |
| Sanofi Pasteur Inc. | 3 | $59 |
| Pfizer | 2 | $40 |
| Mannkind Corporation | 2 | $34 |
| Shield Therapeutics Inc | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,717 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 65 | $40,787 |
| OzempicSemaglutide | 43 | $38,562 |
| JardianceEmpagliflozin | 47 | $37,676 |
| JanuviaSitagliptin Phosphate | 39 | $25,084 |
| KerendiaFinerenone | 29 | $19,027 |
| VascepaIcosapent Ethyl | 27 | $9,057 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $8,071 |
| Repatha SureclickEvolocumab | 13 | $6,717 |
| EliquisApixaban | 11 | $5,783 |
| Icosapent Ethyl | 21 | $3,041 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $1,692 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $1,018 |
| Atorvastatin Calcium | 143 | $971 |
| Losartan Potassium | 68 | $546 |
| Levothyroxine Sodium | 49 | $386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $851 | $38,56243 claims |
| Boehringer IngelheimJardiance | $70 | $37,67647 claims |
| MerckJanuvia, Janumet Xr | $108 | $33,15551 claims |
| BayerKerendia | $327 | $19,02729 claims |
| PfizerEliquis | $40 | $5,78311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.
Other family in Whittier
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.